References

Ahmad SR, Graham DJ, Toyer DP, Wassel R, Mann M (2000) Comparison of pulmonary toxicity risks with anti-androgens (abstract). Pharmacoepidemiology and Drug Safety 9: S121.

Ahmad SR, Singer SJ, Leissa BG (2001) Congestive heart failure associated with itraconazole. Lancet 357: 1766-7.

Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM (1995) Attitudinal survey of adverse drug reaction reporting in the United Kingdom. Br J Clin Pharmacol 39: 223-6.

Blum MD, Graham DJ, McCloskey CA (1994) Tema-floxacin syndrome: review of 95 cases. Clin Infect Dis 18: 946-50.

Breslow NE, Day NE (1980) Statistical Methods in Cancer Research: The Analysis of Case-Control Studies. Lyon: IARC Scientific Publications.

Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Safety 20: 109-17.

Clayton D, Hills M (1993) Statistical Models in Epidemiology. New York: Oxford University Press.

Coultas DB, Zumwalt RE, Black WC, Sobonya RE (1994) The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 150: 967-72.

Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL (1990) Mitichondrial myopathy caused by long-term zidovudine therapy. New Engl J Med 322: 1098-1105.

Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker A, et al. (1991) Mortality and morbidity in patients receiving encainide, flecainide and placebo. New Engl J Med 324: 781-8.

Eland IA, Belton KJ, van Grootheest AC, Meiners AP, Rawlins MD, Stricker BHCh (1999) Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 48: 623 -7.

Frick PA, Cohen LG, Rovers JP (1997) Algorithms used in adverse drug reaction reports: a comparative study. Ann Pharmacother 31: 164-7.

Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ (1999) The safety of newly approved medicines: do recent market removals mean there is a problem? J Am Med Assoc 281: 1728-34.

GAO/HEHS (2000) Adverse Drug Events: The Magni tude of Health Risk is Uncertain Because of Limited Incidence Data. GAO/HEHS-00-21, January.

Graham DJ (1989) Epidemiologic Review of Spontaneous Case Reports of Withdrawal Seizures, Physiologic Dependence and Death Reported with Alprazolam, with Special Attention to Effects of High Dose and Longer Duration Use. Rockville, MD: Psychophar-macologic Drugs Advisory Committee Meeting, Food and Drug Administration, September 20.

Graham DJ, Green L (1999) Epidemiology of Hepato-toxicity with Troglitazone. Bethesda, MD: Metabolic-Endocrine Drugs Advisory Committee Meeting, Food and Drug Administration, March 26.

Graham DJ, Waller PC, Kurz X (2000) View from regulatory agencies. In: Strom BL, ed., Pharmacoepidemiology, 3rd edn. Wiley: New York, pp. 109-24.

Green G (1998) Regional initiatives, past, present and future in the US. In: D'Arcy PF, Harron DWG, eds, Proceedings of the Fourth International Conference on Harmonisation, Brussels 1997 Belfast: Queen's University, pp. 425-9.

Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J (1998) Reducing clozapine-related morbidity and mortality: 5 years experience with the Clozaril National Registry. J Clin Psychiatry 59 (Suppl 3): 3-7.

Inman WHW, Adelstein AM (1969) Rise and fall of asthma mortality in England and Wales in relation to use of pressurized aerosols. Lancet 2: 279-85.

Inman WHW, Weber JCP (1986) The United Kingdom. In: Inman WHW, ed., Monitoring for Drug Safety, 2nd edn. Lancaster: MTP Press Ltd, pp. 13-47.

Johnson JM, Barash D (1991) A review of postmarketing adverse drug experience reporting requirements. FDC Law J 46: 665-72.

Kahn HA, Sempos CT (1989) Statistical Methods in Epidemiology. New York: Oxford University Press.

Kelsey JL, Whittemore AS, Evans AS, Thompson WD (1996) Methods in Observational Epidemiology, 2nd edn. New York: Oxford University Press.

Kennedy DL, Goldman SA, Lillie RB (2000) Spontaneous reporting in the United States. In: Strom BL, ed., Pharmacoepidemiology, 3rd edn. New York: Wiley, pp. 151-74.

La Grenade L, Graham DJ, Trontell A (2000) Fatal myocarditis with clozapine. New Engl Med, in press.

La Grenade L, Kornegay C, Graham DJ (2000) Using publicly available data to derive background rates when evaluating adverse drug reaction reports (abstract). Pharmacoepidemiology and Drug Safety 9: S70-1.

Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 279: 1200-5.

Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, et al. (1993) Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Circulation 88: 492-501.

Meinert CL (1986) Clinical Trials: Design, Conduct and Analysis. New York: Oxford University Press.

Meyboom RHB, Egberts ACG, Edwards RI, Hekster YA, de Koning FHP, Gribnau WJ (1997) Principles of signal detection in pharmacovigilance. Drug Safety 16: 355-65.

Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, et al. (1997) Reports of hypoglycemia associated with the use of ACE inhibitors and other drugs: a case-not case study in the French Pharmacovigilance System database. Br J Clin Pharmacol 44: 513-18.

Murray CJ, Lopez AD (1992) Global health statistics: a compendium of incidence, prevalence, and mortality estimates for over 200 conditions. In: Global Burden of Disease and Injury Series, Vol. 11. Boston: Harvard University Press, pp. 1 -33.

Pere JC, Begaud B, Haramburu F, Albin H (1986) Computerized comparison of six adverse drug reaction assessment procedures. Clin Pharmacol Ther 40: 451-61.

Public Health Advisory (1999) Trovan (trovafloxa-cin/alatrofloxacin mesylate) and risk of liver failure. Food and Drug Administration, June 9. Available from: http://www.fda. gov/cder/news/ trovan/trovan-advisory.htm.

Rogers AS (1987) Adverse drug events: identification and attribution. Drug Intell Clin Pharm 21: 915-20.

Rogers AS, Israel E, Smith CR (1988) Physician knowledge, attitudes and behavior related to reporting adverse drug events. Arch Intern Med 148: 15961600.

Rothman KJ, Greenland S (1998) Modern Epidemiology, 2nd edn. Philadelphia, PA: Lippincott-Raven, pp. 76-7.

Scott HD, Rosenbaum SE, Waters WJ, Colt AM, Andrews LG, Juergens JP, et al. (1987) Rhode Island physicians' recognition and reporting of adverse drug reactions. RI Med J 70: 311-6.

Wiholm BE, Olsson S, Moore N, Waller P (2000) Spontaneous reporting outside the US. In: Strom BL, ed., Pharmacoepidemiology, 3rd edn. New York: Wiley, pp. 175-92.

Was this article helpful?

0 0
Drug Free Life

Drug Free Life

How To Beat Drugs And Be On Your Way To Full Recovery. In this book, you will learn all about: Background Info On Drugs, Psychological Treatments Statistics, Rehab, Hypnosis and Much MORE.

Get My Free Ebook


Post a comment